Skip to content
Open access

Immunohistochemical analysis of phospho-ERK1/2 in odontogenic cysts.

2026 · Journal of Applied Oral Science · Vol 34, pp. e20260462 · 0 citations · 36 references
Medicine

Abstract

Objective

To evaluate the expression levels, cellular localization, and clinicopathological associations of p-ERK1/2 in dentigerous cysts (DCs), odontogenic keratocysts (OKCs), and calcifying odontogenic cysts (COCs). METHODOLOGY Immunohistochemistry was performed on 80 formalin-fixed paraffin-embedded tissue samples (16 DCs, 40 OKCs, and 24 COCs). The immunolocalization and expression levels of p-ERK1/2, a key downstream effector of the MAPK/ERK pathway, were semi-quantitatively evaluated and compared across cyst types. Associations between p-ERK1/2 expression and the clinicopathological characteristics of each lesion were also statistically analyzed.

Results

p-ERK1/2 was predominantly localized in the cytoplasm and/or nucleus of epithelial lining cells of OKCs. Most DCs (68.8%, p=0.006) and COCs (79.2%, p<0.001) showed significantly negative p-ERK1/2 immunostaining. In contrast, the majority of OKCs (75%) exhibited p-ERK1/2 expression. The median immunoreactive score of OKCs (5.49 (1.84-7.84)) was significantly higher than the scores for DCs (p=0.004) and COCs (p<0.001). No significant association was observed between p-ERK1/2 expression and any clinicopathological parameters in the DC and OKC groups. However, p-ERK1/2 expression in COCs was significantly associated with sex (p=0.047).

Conclusions

Elevated p-ERK1/2 expression in OKCs indicates that MAPK/ERK pathway activation may be specifically involved in OKC pathogenesis compared with DCs and COCs. However, the clinicopathological significance of p-ERK1/2 appears to be restricted to selected clinicopathological features in COCs.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.